{"id":28315,"date":"2018-11-12T10:38:31","date_gmt":"2018-11-12T15:38:31","guid":{"rendered":"https:\/\/digital.hbs.edu\/platform-rctom\/submission\/faster-cheaper-better-the-promise-of-machine-learning-for-drug-discovery\/"},"modified":"2018-11-12T10:38:31","modified_gmt":"2018-11-12T15:38:31","slug":"faster-cheaper-better-the-promise-of-machine-learning-for-drug-discovery","status":"publish","type":"hck-submission","link":"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/faster-cheaper-better-the-promise-of-machine-learning-for-drug-discovery\/","title":{"rendered":"Faster, Cheaper, Better: The Promise of Machine Learning for Drug Discovery"},"content":{"rendered":"

Innovation in the pharmaceutical industry has always been labor and cost-intensive. Drug discovery in particular requires intensive research into the molecular basis of diseases and the compounds that interact in effective ways with molecular targets. This happens alongside extensive testing to validate hypotheses and examine other, potentially unanticipated, effects.1<\/sup> There always exists a possibility that a research project goes nowhere, ultimately not being commercialized to bring in revenue. Studies have found that the total cost of developing a new drug to be $1.4 billion (out-of-pocket) to $2.6 billion (capitalized). 2<\/sup> Further, pharmaceutical companies are incentivized to constantly look for new, innovative drugs as patent expiration and the potential for generics can lessen the value of their already commercialized products. Thus, GlaxoSmithKline (GSK) spent \u00a34.5 billion ($5.8 billion USD) on Research & Development in 2017.3<\/sup><\/p>\n

Machine learning has the potential to dramatically alter the product development paradigm for pharmaceuticals. Instead of the existing lengthy, labor-intensive, and expensive process of medicinal chemistry analysis, new technologies are able to use pattern recognition algorithms to identify relationships between \u201csmall molecules and extrapolate them to predict chemical, biological and physical properties of novel compounds.\u201d4<\/sup> Through these \u201cquantitative structure-activity relationship\u201d (QSAR) models, researchers can test chemical modification via machine simulations instead of through physical tests; and as the technology and algorithms improve with additional datasets being added, the relative accuracy of the machine learning techniques will likewise increase.<\/p>\n

\"\"
Illustration by Michele Marconi<\/figcaption><\/figure>\n

Big pharma seeks partners for machine learning expertise<\/strong><\/p>\n

Building robust machine learning capabilities alongside best-in-class traditional research methods is another costly task, despite being a big pharma behemoth. Organizationally, GSK established a specialized drug discovery unit to explore how to use these new techniques to make drug discovery faster, more precise, and cheaper. To get ahead, however, GSK has turned to start-ups who are focused exclusively on artificial intelligence in drug discovery. In 2017, GSK entered two large partnerships to leverage existing machine learning technologies for its own product development: a \u00a333 million ($43 million USD) deal with Exscientia and details undisclosed deal with Insilico Medicine. 5<\/sup><\/p>\n

Exscientia is tasked with using its AI enabled platform to identify new and high-quality drug candidates for 10 disease-related targets as nominated by GSK. Within the platform, the company created a \u201crapid design-make-test cycle\u201d that enables them to learn quickly and design effective compounds with increasingly complex profiles. Exscientia claims their approach has \u201cdelivered candidate-quality molecules in roughly one-quarter of the time, and at one-quarter of the cost of traditional approaches.\u201d6<\/sup><\/p>\n

Insilico will focus on vaccine discovery using biologics (substances made from living organisms). Their technology builds \u201cnetwork models of common [disease] host organisms\u201d and runs simulations of various bioprocesses to identify which candidate vaccines will be safest and most effective. 7<\/sup> The two-year partnership also includes explicit goals for using learnings to improve upon the existing processes.<\/p>\n

The longer-term perspective<\/strong><\/p>\n

Despite a significant amount of media attention and hype around machine learning, many aspects of the technology are still unproven. There isn\u2019t consensus within the life sciences industries about the potential and application of these technologies and GSK must continue to be skeptical and critical of partners\u2019 technologies.8<\/sup> Continuing to work with multiple partners, instead of relying on just one technology, and understanding how the inputs and outputs differ between them will be critical in ensuring that GSK is able to reliably generate the most value.<\/p>\n

Further, GSK must prioritize the development of in-house platforms and expertise on machine learning. This is important in the shorter term in order to knowledgeably assess their partners\u2019 work products and move forward in a high-risk business with a strong understanding of their drugs. In the long term, continuing to work with partners will put GSK\u2019s competitive advantages in innovation at risk. Exscientia, for example, has also signed partnership deals with Evotec and Sanofi.9<\/sup> If machine learning becomes a predominant and integral part of drug discovery, GSK must have the capabilities within their organization to succeed.<\/p>\n

GSK was not on the forefront of machine learning for drug discovery. As the field of advanced data analytics through artificial intelligence grows, GSK should strive to be the ones to identify new research, or additional ways to take existing technologies and apply across its extensive business (including in manufacturing and distribution). However, should these new technologies replace existing traditional methods of research altogether? If so \u2013 how fast, and are there additional risks to consider? What are the costs required to develop this in-house, or to acquire the knowledge from others? Is that value proposition worth it?<\/p>\n

\u00a0<\/strong><\/p>\n

(750 words)<\/p>\n

 <\/p>\n

Sources:<\/strong><\/p>\n

1<\/sup> Julia James, \u201cWhy drug development is time consuming and expensive (hint: it’s hard),\u201d Scope<\/em> (blog), Stanford University School of Medicine, July 21, 2010, [https:\/\/scopeblog.stanford.edu\/2010\/07\/21\/mochly_rosen_lecture], accessed November 2018.<\/p>\n

2<\/sup> Joseph A. DiMasi, \u201cInnovation in the pharmaceutical industry: New estimates of R&D costs.\u201d Journal of Health Economics<\/em> 47 (May 2016): 20-33.<\/p>\n

3 <\/sup>GlaxoSmithKline, 2017 Annual Report. [https:\/\/www.gsk.com\/media\/4751\/annual-report.pdf], accessed November 2018.<\/p>\n

4<\/sup> Yu-Chen Lo, \u201cMachine learning in chemoinformatics and drug discovery.\u201d Drug Discovery Today <\/em>23(8) (August 2018): 1538-1546.<\/p>\n

5 <\/sup>Amirah Al Idrus, \u201cGlaxoSmithKline taps Baltimore\u2019s Insilico for AI-based drug discovery,\u201d Fierce Biotech, August 16, 2017, [https:\/\/www.fiercebiotech.com\/medtech\/gsk-taps-baltimore-s-insilico-for-ai-based-drug-discovery], accessed November 2018.<\/p>\n

6 <\/sup>\u201cExscientia enters strategic drug discovery collaboration with GSK,\u201d press release, July 2, 2017, on Exscientia website, [https:\/\/www.exscientia.co.uk\/news\/2017\/7\/2\/exscientia-collaboration-gsk], accessed November 2018.<\/p>\n

7 <\/sup>\u201cInsilico and GSK establish a collaboration to promote biomanufacturing of the future,\u201d press release, March 1, 2017, on Insilico Biotechnology website, [http:\/\/www.insilico-biotechnology.com\/en\/insilico-gsk], accessed November 2018.<\/p>\n

8 <\/sup>\u201cDrug discovery and development may never be the same \u2014 the life sciences are embracing AI,\u201d STAT News,<\/em> November 6, 2018, [https:\/\/www.statnews.com\/sponsor\/2018\/11\/06\/life-sciences-are-embracing-ai], accessed November 2018.<\/p>\n

9 <\/sup>Evelyn Warner, \u201cEurope\u2019s Brightest Stars: The 9 Best Biotech Companies of 2017,\u201d LABIOTECH, <\/em>May 12, 2017, [https:\/\/labiotech.eu\/tops\/best-biotech-companies-2017\/], accessed November 2018.<\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

GSK is rethinking its drug discovery pipeline using machine learning<\/p>\n","protected":false},"author":11529,"featured_media":28324,"comment_status":"open","ping_status":"closed","template":"","categories":[4319,2130,4318,346],"class_list":["post-28315","hck-submission","type-hck-submission","status-publish","has-post-thumbnail","hentry","category-big-pharma","category-drug-discovery","category-gsk","category-machine-learning","hck-taxonomy-organization-gsk","hck-taxonomy-industry-pharmaceutical","hck-taxonomy-country-united-kingdom"],"connected_submission_link":"https:\/\/d3.harvard.edu\/platform-rctom\/assignment\/rc-tom-challenge-2018\/","yoast_head":"\nFaster, Cheaper, Better: The Promise of Machine Learning for Drug Discovery - Technology and Operations Management<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/faster-cheaper-better-the-promise-of-machine-learning-for-drug-discovery\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Faster, Cheaper, Better: The Promise of Machine Learning for Drug Discovery - Technology and Operations Management\" \/>\n<meta property=\"og:description\" content=\"GSK is rethinking its drug discovery pipeline using machine learning\" \/>\n<meta property=\"og:url\" content=\"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/faster-cheaper-better-the-promise-of-machine-learning-for-drug-discovery\/\" \/>\n<meta property=\"og:site_name\" content=\"Technology and Operations Management\" \/>\n<meta property=\"og:image\" content=\"https:\/\/d3.harvard.edu\/platform-rctom\/wp-content\/uploads\/sites\/4\/2018\/11\/gsk-23andme-2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"4387\" \/>\n\t<meta property=\"og:image:height\" content=\"2050\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/submission\\\/faster-cheaper-better-the-promise-of-machine-learning-for-drug-discovery\\\/\",\"url\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/submission\\\/faster-cheaper-better-the-promise-of-machine-learning-for-drug-discovery\\\/\",\"name\":\"Faster, Cheaper, Better: The Promise of Machine Learning for Drug Discovery - Technology and Operations Management\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/submission\\\/faster-cheaper-better-the-promise-of-machine-learning-for-drug-discovery\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/submission\\\/faster-cheaper-better-the-promise-of-machine-learning-for-drug-discovery\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2018\\\/11\\\/gsk-23andme-2.jpg\",\"datePublished\":\"2018-11-12T15:38:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/submission\\\/faster-cheaper-better-the-promise-of-machine-learning-for-drug-discovery\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/submission\\\/faster-cheaper-better-the-promise-of-machine-learning-for-drug-discovery\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/submission\\\/faster-cheaper-better-the-promise-of-machine-learning-for-drug-discovery\\\/#primaryimage\",\"url\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2018\\\/11\\\/gsk-23andme-2.jpg\",\"contentUrl\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/wp-content\\\/uploads\\\/sites\\\/4\\\/2018\\\/11\\\/gsk-23andme-2.jpg\",\"width\":4387,\"height\":2050,\"caption\":\"19 April 2018, Germany, Munich: The logo of GlaxoSmithKline (GSK) at the company's offices. Photo: Sven Hoppe\\\/dpa (Photo by Sven Hoppe\\\/picture alliance via Getty Images)\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/submission\\\/faster-cheaper-better-the-promise-of-machine-learning-for-drug-discovery\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Submissions\",\"item\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/submission\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Faster, Cheaper, Better: The Promise of Machine Learning for Drug Discovery\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/#website\",\"url\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/\",\"name\":\"Technology and Operations Management\",\"description\":\"MBA Student Perspectives\",\"potentialAction\":[{\"@type\":\"性视界Action\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/d3.harvard.edu\\\/platform-rctom\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Faster, Cheaper, Better: The Promise of Machine Learning for Drug Discovery - Technology and Operations Management","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/faster-cheaper-better-the-promise-of-machine-learning-for-drug-discovery\/","og_locale":"en_US","og_type":"article","og_title":"Faster, Cheaper, Better: The Promise of Machine Learning for Drug Discovery - Technology and Operations Management","og_description":"GSK is rethinking its drug discovery pipeline using machine learning","og_url":"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/faster-cheaper-better-the-promise-of-machine-learning-for-drug-discovery\/","og_site_name":"Technology and Operations Management","og_image":[{"width":4387,"height":2050,"url":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-content\/uploads\/sites\/4\/2018\/11\/gsk-23andme-2.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/faster-cheaper-better-the-promise-of-machine-learning-for-drug-discovery\/","url":"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/faster-cheaper-better-the-promise-of-machine-learning-for-drug-discovery\/","name":"Faster, Cheaper, Better: The Promise of Machine Learning for Drug Discovery - Technology and Operations Management","isPartOf":{"@id":"https:\/\/d3.harvard.edu\/platform-rctom\/#website"},"primaryImageOfPage":{"@id":"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/faster-cheaper-better-the-promise-of-machine-learning-for-drug-discovery\/#primaryimage"},"image":{"@id":"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/faster-cheaper-better-the-promise-of-machine-learning-for-drug-discovery\/#primaryimage"},"thumbnailUrl":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-content\/uploads\/sites\/4\/2018\/11\/gsk-23andme-2.jpg","datePublished":"2018-11-12T15:38:31+00:00","breadcrumb":{"@id":"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/faster-cheaper-better-the-promise-of-machine-learning-for-drug-discovery\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/d3.harvard.edu\/platform-rctom\/submission\/faster-cheaper-better-the-promise-of-machine-learning-for-drug-discovery\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/faster-cheaper-better-the-promise-of-machine-learning-for-drug-discovery\/#primaryimage","url":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-content\/uploads\/sites\/4\/2018\/11\/gsk-23andme-2.jpg","contentUrl":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-content\/uploads\/sites\/4\/2018\/11\/gsk-23andme-2.jpg","width":4387,"height":2050,"caption":"19 April 2018, Germany, Munich: The logo of GlaxoSmithKline (GSK) at the company's offices. Photo: Sven Hoppe\/dpa (Photo by Sven Hoppe\/picture alliance via Getty Images)"},{"@type":"BreadcrumbList","@id":"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/faster-cheaper-better-the-promise-of-machine-learning-for-drug-discovery\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/d3.harvard.edu\/platform-rctom\/"},{"@type":"ListItem","position":2,"name":"Submissions","item":"https:\/\/d3.harvard.edu\/platform-rctom\/submission\/"},{"@type":"ListItem","position":3,"name":"Faster, Cheaper, Better: The Promise of Machine Learning for Drug Discovery"}]},{"@type":"WebSite","@id":"https:\/\/d3.harvard.edu\/platform-rctom\/#website","url":"https:\/\/d3.harvard.edu\/platform-rctom\/","name":"Technology and Operations Management","description":"MBA Student Perspectives","potentialAction":[{"@type":"性视界Action","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/d3.harvard.edu\/platform-rctom\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-json\/wp\/v2\/hck-submission\/28315","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-json\/wp\/v2\/hck-submission"}],"about":[{"href":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-json\/wp\/v2\/types\/hck-submission"}],"author":[{"embeddable":true,"href":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-json\/wp\/v2\/users\/11529"}],"replies":[{"embeddable":true,"href":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-json\/wp\/v2\/comments?post=28315"}],"version-history":[{"count":0,"href":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-json\/wp\/v2\/hck-submission\/28315\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-json\/wp\/v2\/media\/28324"}],"wp:attachment":[{"href":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-json\/wp\/v2\/media?parent=28315"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/d3.harvard.edu\/platform-rctom\/wp-json\/wp\/v2\/categories?post=28315"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}